Example: Heart Attack

Clinical Trials Sponsored by Sangart

Total 10 results

NCT01973504

Withdrawn

Phase 2c Dose Comparison Study of MP4OX in Trauma

Conditions: Trauma; Hemorrhagic Shock; Lactic Acidosis
NCT01925001

Withdrawn

Phase 2 Study of MP4CO to Treat Vaso-occlusive Sickle Crisis

Conditions: Anemia, Sickle Cell; Sickle Cell Anemia; Sickle Cell Disease; Sickle Cell Disorders; Hemoglobin SC Disease; Sickle Cell Hemoglobin C Disease
NCT01356485

Completed

Safety Study of MP4CO in Adult Sickle Cell Patients

Conditions: Anemia, Sickle Cell; Sickle Cell Anemia; Sickle Cell Disease; Sickle Cell Disorders; Hemoglobin SC Disease; Sickle Cell Hemoglobin C Disease
NCT01262196

Completed

Phase IIb Study of MP4OX in Traumatic Hemorrhagic Shock Patients

Conditions: Shock, Hemorrhagic; Shock, Traumatic; Acidosis, Lactic
NCT01004198

Completed

Phase IIa Study of MP4OX in Traumatic Hemorrhagic Shock Patients

Conditions: Shock, Hemorrhagic; Shock, Traumatic; Acidosis, Lactic
NCT00633659

Completed

Pilot Study of Hemospan® in Patients With Chronic Critical Limb Ischemia

Conditions: Vascular Disease; Critical Lower Limb Ischemia
NCT00494949

Completed

Increasing Dose Safety Study of Hemospan in Orthopedic Surgery Patients

Conditions: Hypotension; Hypoxia
NCT00425334

Completed

Safety Study of Hemospan® in Prostatectomy Patients

Conditions: Blood Loss, Surgical; Prostate Cancer; Surgery
NCT00421200

Completed

Phase III Study of Hemospan® to Prevent Hypotension in Hip Arthroplasty

Conditions: Hypotension; Ischemia
NCT00420277

Completed

Phase III Study of Hemospan® for Treating Hypotension in Hip Arthroplasty

Conditions: Hypotension; Ischemia